Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Johnson & Johnson Recalls Some Batches Of Antipsychotic Drug Over Mold Concerns-DJ


Wednesday, 11 Sep 2013 05:49pm EDT 

Dow Jones reported that Johnson & Johnson (JNJ) recalled another product on Wednesday, pulling some vials of its antipsychotic treatment Risperdal Consta after discovering mold during routine quality testing. The New Brunswick, N.J., health-products maker estimates that 5,000 of the 70,000 vials made in a single lot last year remain unused in doctor's offices, community mental health centers and pharmacies and must be withdrawn. Because it is injected, Risperdal Consta is stored and given at the clinics, rather than the patients keeping and taking the drug themselves. J&J, which announced the recall in a letter to doctors and on company Websites, said the Alternaria alternata mold that was discovered is found commonly in the environment and could cause infections around the area where the injection is given. The Risperdal Consta that was recalled was the 25mg dose. It was made by another company, Alkermes PLC (ALKS), and shipped from Jan. 14 to May 20, 2013, according to J&J. 

Company Quote

103.075
-0.365 -0.35%
27 Aug 2014